HIV vaccine trial participation among ethnic minority communities: Barriers, motivators, and implications for recruitment

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 2, 2006, Pages 210-217

  Newman, Peter A ^a   Duan, Naihua ^b   Roberts, Kathleen J ^c   Seiden, Danielle ^b   Rudy, Ellen T ^d   Swendeman, Dallas ^b   Popova, Svetlana ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Division of Sexually Transmitted Disease   (United States)

Author keywords

African Americans; Barriers; HIV vaccine trial; Latinos; Qualitative research; Research participation

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AFRICAN AMERICAN; ALTRUISM; ARTICLE; ATTITUDE TO ILLNESS; CLINICAL STUDY; COMPUTER PROGRAM; DRUG EFFICACY; DRUG INDUCED DISEASE; ETHNIC GROUP; FEMALE; FINANCE; HAIR LOSS; HEALTH INSURANCE; HISPANIC; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; LIVER DISEASE; LOWEST INCOME GROUP; MALE; MINORITY GROUP; MOTIVATION; NORMAL HUMAN; PRIORITY JOURNAL; REFUSAL TO PARTICIPATE; RESEARCH SUBJECT; RISK ASSESSMENT; SAMPLING; SEMI STRUCTURED INTERVIEW; SEROLOGY; STIGMA; UNITED STATES; UNSPECIFIED SIDE EFFECT; ATTITUDE TO HEALTH; CLINICAL TRIAL; ETHNOLOGY; INFORMATION PROCESSING; PATIENT PARTICIPATION; POVERTY; PSYCHOLOGICAL ASPECT; SOCIAL PSYCHOLOGY;

AFRICAN AMERICANS; AIDS VACCINES; CLINICAL TRIALS; FEMALE; FOCUS GROUPS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HISPANIC AMERICANS; HUMANS; LOS ANGELES; MALE; MINORITY GROUPS; PATIENT PARTICIPATION; POVERTY; PREJUDICE;

EID: 33645285632     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000179454.93443.60     Document Type: Article

References (62)

1. Burton DB, Desrosiers RC, Doms RW, et al. A sound rationale needed for Phase III HIV-1 vaccine trials. Science. 2004;303:316.
2. International AIDS Vaccine Initiative. Ongoing trials of preventive HIV vaccines. International AIDS Vaccine Initiative. Available at: http://www.iavireportonline.org/specials/OngoingTrialsofPreventiveHIV-Vaccines. pdf.
3. Cohen J. HIV/AIDS: vaccine results lose significance under scrutiny. Science. 2003;299:1495.
4. VaxGen. VaxGen announces results of its Phase III HIV vaccine trial in Thailand. Vaccine fails to meet endpoints. Available at: www.vaxgen.com/pressroom/index.html.
5. Watanabe ME. Skeptical scientists skewer VaxGen statistics. Nat Med. 2003;9:376.
6. Klein M. Prospects and challenges for prophylactic and therapeutic HIV vaccines. Vaccine. 2003;21:616-619.
7. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2003. 2004:15. Available at: http://www.cdc.gov/hiv/stats/2003surveillancereport.pdf
8. Centers for Disease Control and Prevention. HIV/AIDS among racial/ethnic minority men who have sex with men - United States, 1989-1998. Morb Mortal Wkly Rep. 2000;49:4-11.
9. Gilbert P, Popovic V, Gurwith M, et al. Immunologic responses to rgp120 vaccine and correlation with the risk of HIV infection: results from the world's first HIV vaccine efficacy trial [abstract 147]. In: Program and Abstracts for AIDS Vaccine 2003 (New York). Alexandria, VA: Foundation for AIDS Vaccine Research and Development; 2003:92.
10. Kahn P. VaxGen: are there hints of race-based effects? AIDScience. 2002;3:1-4.
11. Montefiori DC, Metch B, McElrath MJ, et al. HIV Vaccine Trials Network. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis. 2004;190:1962-1969.
12. de Bruyn G, Rossini AJ, Chiu YL, et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine. 2004;22:704-713.
13. Cohen J. Public health: AIDS vaccine trial produces disappointment and confusion. Science. 2003;299:1290-1291.
14. VaxGen. VaxGen announces initial results of its Phase III AIDS vaccine trial. 2003. Available at: http://www.vaxgen.com/pressroom/index.html.
15. Sternberg S. AIDS fight hits racial divide. USA Today. March 31, 2003. Available at: http://www.usatoday.com/news/health/2003-03-31-vaxgen-cover_x.htm.
16. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial. J Acquir Immune Defic Syndr. 2004;36:604-612.
17. Halpern SD, Metzger DS, Berlin JA, et al. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr. 2001;27:281-288.
18. Sengupta S, Strauss RP, DeVellis R, et al. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr. 2000;24:275-284.
19. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med. 2002;346:1373-1382.
20. El-Sadr W, Capps L. The challenge of minority recruitment in clinical trials for AIDS. JAMA. 1992;267:954-957.
21. Stone VE, Mauch MY, Steger K, et al. Race, gender, drug use, and participation in AIDS clinical trials - lessons from a municipal hospital cohort. J Gen Intern Med. 1997;12:150-157.
22. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr. 1999;20:164-171.
23. Koblin BA, Holte S, Lenderking B, et al. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV Network for Prevention Trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr. 2000;24:451-457.
24. MacQueen KM, Buchbinder S, Douglas JM, et al. The decision to enroll in HIV vaccine efficacy trials: concerns elicited from gay men at increased risk for HIV infection. AIDS Res Hum Retroviruses. 1994;10(Suppl 2):S261-S264.
25. O'Connell JM, Hogg RS, Chan K, et al. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr. 2002;31:521-528.
26. Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three US communities. J Acquir Immune Defic Syndr. 2001;26:63-71.
27. Vlahov D, Astemborski J, Solomon L, et al. Interest in HIV vaccines among injection drug users in Baltimore, MD. AIDS Res Hum Retroviruses. 1994;10:265-268.
28. Douglas JMJ, Judson FN, Parks JP, et al. Participation of homosexual/bisexual men in preventive HIV vaccine trials: baseline attitudes and concerns and predicted behaviors during trials. AIDS Res Hum Retroviruses. 1994;10(Suppl 2):S257-S260.
29. Gross M, Seage GR, Mayer KH, et al. Interest among gay/bisexual men in greater Boston in participating in clinical trials of preventive HIV vaccines. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:406-412.
30. Wiley JA, Osmond D, Page K, et al. Willingness of young gay and bisexual men to participate in phase III vaccine trials: baseline survey results from the San Francisco Young Men's Health Survey. AIDS Res Hum Retroviruses. 1994;10(Suppl 2):S269.
31. Bartholow BN, MacQueen KM, Douglas JM, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.
32. Buchbinder SP, Douglas JMJ, McKirnan DJ, et al. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174:954-961.
33. Koblin BA, Avrett S, Taylor PE, et al. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:165-171.
34. Tello J, Soong SJ, Hunter B, et al. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci. 1998;315:11-16.
35. Brown-Peterside P, Chiasson MA, Ren L, et al. Involving women in HIV vaccine efficacy trials: lessons learned from a vaccine preparedness study in New York City. J Urban Health. 2000;77:425-437.
36. United States Census Bureau. Annual Resident Population Estimates of the United States by Age, Race, and Hispanic or Latino Origin: April 1, 2000 to July 1, 2002. Hyattsville: United States Census Bureau; 2003.
37. Diamant AL, Hays RD, Morales LS, et al. Delays and unmet need for health care among adult primary care patients in a restructured urban public health system. Am J Public Health. 2004;94:783-789.
38. Frankel MR, Shapiro MF, Duan N, et al. National probability samples in studies of low-prevalence diseases, part 2: designing and implementing the HIV cost and services utilization study sample. Health Serv Res. 1999;34:969-992.
39. Singleton RJ, Straits BC. Approaches to Social Research. 3rd ed. New York: Oxford University Press; 1999.
40. Morgan DL. The Focus Group Guidebook. Thousand Oaks: Sage Publications; 1998.
41. Strauss A, Corbin J. Basics of Qualitative Research: Grounded Theory Procedures and techniques. Newbury Park: Sage Publications; 1990.
42. Diaz R. Latino Gay Men and HIV: Culture, Sexuality and Risk Behavior. Boston: Routledge Kegan Paul; 1998.
43. Flores G. Culture and the patient-physician relationship: achieving cultural competency in health care. J Pediatr. 2000;136:14-23.
44. Airhihenbuwa CO, DiClemente RJ, Wingood GM, et al. HIV/AIDS education and prevention among African-Americans: a focus on culture. AIDS Educ Prev. 1992;4:267-276.
45. Wingood GM, DiClemente RJ. Cultural, gender, and psychosocial influences on HIV related behavior of African-American female adolescents: implications for the development of tailored prevention programs. Ethn Dis. 1992;2:381-388.
46. Bartholow BN, MacQueen KM, Douglas JM Jr, et al. Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:108-115.
47. Besch CL. Compliance in clinical trials. AIDS. 1995;9:1-10.
48. Meyers K, Metzger DS, Navaline H, et al. HIV vaccine trials: will intravenous drug users enroll? Am J Public Health. 1994;84:761-766.
49. Strathdee SA, Hogg RS, Cornelisse PGA, et al. Factors associated with willingness to participate in HIV vaccine trials among HIV-negative injection drug users and young gay and bisexual men. AIDS Behav. 2000;4:271-278.
50. Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three US communities. J Acquir Immune Defic Syndr. 2001;26:63-71.
51. Flaskerud JH, Uman G. Acculturation and its effects on self-esteem among immigrant Latina women. Behav Med. 1996;22:123-133.
52. Gomez CA, Marin BV. Gender, culture and power: barriers to HIV prevention strategies. J Sex Res. 1996;33:355-362.
53. Marin BV. HIV prevention in the Hispanic community: sex, culture, and empowerment. J Transcult Nurs. 2003;14:186-192.
54. Marin BV, Gomez CA, Tschann JM, et al. Condom use in unmarried Latino men: a test of cultural constructs. Health Psychol. 1997;16:458-467.
55. Guinan ME. Black communities' belief in "AIDS as genocide." A barrier to overcome for HIV prevention. Ann Epidemiol. 1993;3:193-195.
56. Thomas SB, Crouse-Quinn S. Public health then and now. The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the Black community. Am J Public Health. 1991;81:1498-1504.
57. Newman PA, Duan N, Rudy ET, et al. HIV risk and prevention in a post-vaccine context. Vaccine. 2004;22:1954-1963.
58. Klonoff EA, Landrine H. Do blacks believe that HIV/AIDS is a government conspiracy against them? Prev Med. 1999;28:451-457.
59. Jones JH. Bad Blood: The Tuskegee Syphilis Experiment. New York: Free Press; 1981.
60. Dunlap C. No Comprendo: The Utility of English Language Patient Education Materials Translated into Spanish. Policy Brief. Claremont: Tomás Rivera Policy Institute; 2000.
61. Duan N. Listening to consumers and HIV vaccine preparedness. Lancet. 2005;365:1119-1121.
62. Newman PA, Duan N, Rudy ET, et al. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS. 2004;18:691-701.